We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
2
0 active
Approvals
14
Total approvals
Agencies
4
Regulatory bodies
Founded
N/A
Completed
100.0%
NMPA
National Medical Products Administration
3
FDA
Food and Drug Administration
PHILIPPINES
Philippines FDA
5
NPRA
National Pharmaceutical Regulatory Agency
- Indian pharmaceutical companies including Hetero Labs, Cipla, Annora Pharma, and Natco Pharma have successfully won bids to supply generic drugs to Chinese hospitals through the country's volume-based procurement process. - Hetero Drugs and Cipla secured contracts to supply one billion tablets of Dapagliflozin, a diabetes medication that dominates China's small molecule drug market with sales exceeding 8 billion RMB ($1.14 billion). - The breakthrough represents a significant opportunity for Indian firms to penetrate China's pharmaceutical market, traditionally dominated by multinational companies, despite pricing pressures and competition from cost-advantaged local manufacturers.
